PapersFlow Research Brief
Cardiovascular Issues in Pregnancy
Research Guide
What is Cardiovascular Issues in Pregnancy?
Cardiovascular issues in pregnancy refer to the management, diagnosis, and outcomes of cardiovascular diseases occurring during pregnancy, including peripartum cardiomyopathy, spontaneous coronary artery dissection, and congenital heart disease, with focus on maternal and fetal outcomes, risk factors, and therapeutic management.
This field encompasses 47,915 papers on cardiovascular diseases in pregnancy. Key conditions addressed include peripartum cardiomyopathy, spontaneous coronary artery dissection, and congenital heart disease. Research emphasizes maternal outcomes, fetal outcomes, risk factors, and therapy.
Topic Hierarchy
Research Sub-Topics
Peripartum Cardiomyopathy
Researchers investigate etiology, risk factors, and management of PPCM, including biomarkers and long-term outcomes. Studies cover pathophysiology from inflammation to genetics.
Spontaneous Coronary Artery Dissection in Pregnancy
This sub-topic examines SCAD incidence, hormonal triggers, and interventional strategies during peripartum periods. Research includes imaging and conservative management outcomes.
Congenital Heart Disease in Pregnancy
Studies assess maternal and fetal risks, hemodynamic changes, and delivery planning in women with CHD. Focus includes pulmonary hypertension and mechanical valves.
Pulmonary Hypertension in Pregnancy
Research evaluates diagnosis, targeted therapies, and multidisciplinary care for PH during gestation. Topics include right heart failure risks and postpartum monitoring.
Valvular Heart Disease Management in Pregnancy
This area covers anticoagulation, surgical timing, and lesion-specific risks for VHD patients. Studies analyze prosthetic valves and native valve progression.
Why It Matters
Cardiovascular issues in pregnancy directly affect maternal and fetal health, requiring specialized management to optimize outcomes. "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy" by Regitz‐Zagrosek et al. (2018) provides evidence-based recommendations for diagnosing and treating conditions like congenital heart disease and pulmonary hypertension during pregnancy, influencing clinical practice across Europe. For instance, these guidelines address therapy for pulmonary arterial hypertension, building on findings from "Bosentan Therapy for Pulmonary Arterial Hypertension" by Rubin et al. (2002), which showed bosentan at 125 mg twice daily improves symptoms, relevant for pregnant patients with this complication. In valvular heart disease, prevalent in pregnancy, "ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease" by Bonow et al. (2006) offers management strategies cited 8502 times, aiding decisions on interventions to prevent adverse maternal events.
Reading Guide
Where to Start
"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy" by Regitz‐Zagrosek et al. (2018), as it directly addresses pregnancy-specific cardiovascular management, providing a practical overview of diagnosis, risk factors, and therapy for conditions like congenital heart disease and pulmonary hypertension.
Key Papers Explained
"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy" by Regitz‐Zagrosek et al. (2018) synthesizes prior work like "ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease" by Bonow et al. (2006), adapting valvular management to pregnancy. It builds on "Updated Clinical Classification of Pulmonary Hypertension" by Simonneau et al. (2013) and "Bosentan Therapy for Pulmonary Arterial Hypertension" by Rubin et al. (2002), incorporating endothelin antagonists into pregnancy protocols. "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" by Humbert et al. (2022) updates classification and therapy relevant to high-risk pregnancies.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Guidelines like "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" by Humbert et al. (2022) represent the latest on pulmonary hypertension management, applicable to pregnancy. No recent preprints or news from the last 12 months suggest focus remains on refining existing therapies for maternal-fetal outcomes in valvular and congenital heart diseases.
Papers at a Glance
Frequently Asked Questions
What are the main cardiovascular conditions studied in pregnancy?
Key conditions include peripartum cardiomyopathy, spontaneous coronary artery dissection, and congenital heart disease. Research focuses on their management, diagnosis, and maternal and fetal outcomes. Risk factors and therapeutic approaches are central to the 47,915 papers in this field.
How do guidelines recommend managing cardiovascular diseases during pregnancy?
"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy" by Regitz‐Zagrosek et al. (2018) outline diagnosis and treatment strategies for conditions like valvular heart disease and pulmonary hypertension. These peer-reviewed guidelines emphasize risk assessment for maternal and fetal outcomes. They integrate therapies safe for pregnancy.
What is the role of pulmonary hypertension in pregnancy?
"Updated Clinical Classification of Pulmonary Hypertension" by Simonneau et al. (2013) and "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" by Humbert et al. (2022) classify and guide treatment of pulmonary hypertension, relevant to pregnancy complications. These works, with 4162 and 3197 citations respectively, inform management of this high-risk condition. Therapy like bosentan targets endothelin pathways.
What treatments are effective for pulmonary arterial hypertension associated with pregnancy?
"Bosentan Therapy for Pulmonary Arterial Hypertension" by Rubin et al. (2002) demonstrated that bosentan at 125 mg twice daily benefits patients by improving symptoms and is well-tolerated. "Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension" by Galiè et al. (2005) showed sildenafil enhances exercise capacity and hemodynamics. These apply to pregnancy contexts under specialized guidelines.
How is valvular heart disease managed in pregnant patients?
"ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease" by Bonow et al. (2006), with 8502 citations, provide strategies for valvular conditions common in pregnancy. "Burden of valvular heart diseases: a population-based study" by Nkomo et al. (2006) quantifies prevalence, aiding risk stratification. Management balances maternal needs with fetal safety.
What is the current state of research on cardiovascular issues in pregnancy?
The field includes 47,915 works focusing on outcomes and therapy for diseases like congenital heart disease. "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy" by Regitz‐Zagrosek et al. (2018) represents key guidance with 2147 citations. No recent preprints or news coverage from the last 12 months indicate stable guideline-driven progress.
Open Research Questions
- ? How do pregnancy-specific hemodynamic changes alter outcomes in pulmonary hypertension compared to non-pregnant patients?
- ? What are the long-term maternal and fetal risks of bosentan or sildenafil use during pregnancy for pulmonary arterial hypertension?
- ? Which valvular interventions minimize adverse events in pregnant women with severe disease?
- ? How can risk stratification models for peripartum cardiomyopathy be improved using population-based data?
- ? What therapeutic protocols best balance congenital heart disease management with fetal development?
Recent Trends
The field holds steady at 47,915 papers with no reported 5-year growth rate. "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" by Humbert et al. marks the most recent high-citation update (3197 citations), building on classifications from Simonneau et al. (2013).
2022No preprints or news in the last 12 months indicate reliance on established guidelines like Regitz‐Zagrosek et al. .
2018Research Cardiovascular Issues in Pregnancy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cardiovascular Issues in Pregnancy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers